"We are on target for meeting our 1993 clinical development objectives," said Robert C. Bishop, Ph.D., President and Chief Executive Officer of AutoImmune. "The Phase II trial of AI-200 for rheumatoid arthritis will be completed on schedule in the second quarter; patient enrollment in our Phase II study of AI-300 for uveitis is steadily increasing; and we are now completing our plans for Phase II/III trials of AI-100 for multiple sclerosis," Dr. Bishop stated.
"During the first quarter, we also made excellent progress in building AutoImmune's corporate infrastructure. We completed construction of our new laboratory facilities, and have continued to attract outstanding scientific and regulatory affairs personnel," Dr. Bishop added.
AutoImmune is developing pharmaceutical products based on the principle of oral tolerance for the treatment of immune system disorders, including multiple sclerosis, rheumatoid arthritis and uveitis.
R e t u r n